Literature DB >> 9750027

Clinical pharmacology of camptothecins.

L Iyer1, M J Ratain.   

Abstract

Camptothecins (CPTs) are a unique class of chemotherapeutic agent which inhibit DNA synthesis by inhibiting topoisomerase I activity. Structure-activity studies on the original CPT alkaloid led to the development of the new analogues irinotecan (CPT-11), topotecan, and 9-aminocamptothecin, which have improved water solubility and lower toxicity. CPT analogues exhibit interesting pharmacokinetic/pharmacodynamic and metabolic properties that are of major research and clinical interest. This review describes the clinical pharmacology of these 3 CPT analogues. Specific areas such as absorption after extravascular administration, pharmacokinetic/pharmacodynamic variability, metabolism, and administration in special populations are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9750027     DOI: 10.1007/s002800051077

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  12 in total

Review 1.  Chemoradiotherapy for colorectal cancer.

Authors:  N Andre; W Schmiegel
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

2.  The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.

Authors:  Mehmet Artac; Hakan Bozcuk; Sacide Pehlivan; Songül Akcan; Mustafa Pehlivan; Tugce Sever; Mustafa Ozdogan; Burhan Savas
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-12       Impact factor: 4.553

3.  What is the potential role of hepatic arterial infusion chemo-therapy in the current armamentorium against colorectal cancer.

Authors:  Ozkän Kanat; Alexandra Gewirtz; Nancy Kemeny
Journal:  J Gastrointest Oncol       Date:  2012-06

4.  In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines.

Authors:  Wolfgang Fiebiger; Ulrike Olszewski; Ernst Ulsperger; Klaus Geissler; Gerhard Hamilton
Journal:  Clin Transl Oncol       Date:  2011-01       Impact factor: 3.405

5.  The dietary flavonoid apigenin enhances the activities of the anti-metastatic protein CD26 on human colon carcinoma cells.

Authors:  Emilie C Lefort; Jonathan Blay
Journal:  Clin Exp Metastasis       Date:  2011-02-05       Impact factor: 5.150

6.  Ubiquitin-family modifications of topoisomerase I in camptothecin-treated human breast cancer cells.

Authors:  Ragu Kanagasabai; Shujun Liu; Samir Salama; Edith F Yamasaki; Liwen Zhang; Kari B Greenchurch; Robert M Snapka
Journal:  Biochemistry       Date:  2009-04-14       Impact factor: 3.162

7.  Pharmacogenetic pathway analysis of irinotecan.

Authors:  G L Rosner; J C Panetta; F Innocenti; M J Ratain
Journal:  Clin Pharmacol Ther       Date:  2008-04-16       Impact factor: 6.875

8.  UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.

Authors:  Christoph Schulz; Volker Heinemann; Andreas Schalhorn; Nikolas Moosmann; Thomas Zwingers; Stefan Boeck; Clemens Giessen; Hans-Joachim Stemmler
Journal:  World J Gastroenterol       Date:  2009-10-28       Impact factor: 5.742

Review 9.  Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.

Authors:  Jörg T Hartmann; Hans-Peter Lipp
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

10.  Oxaliplatin but not irinotecan impairs posthepatectomy liver regeneration in a murine model.

Authors:  Perry A Soriano; Nian Liu; Erick Castillo; Brock Foster; Avo Artinyan; Joseph Kim; Wendong Huang; Lawrence D Wagman
Journal:  Int J Hepatol       Date:  2011-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.